Back to the full story2 sources · Eli Lilly beat earnings and raised its forecast as weight loss drug sales surged◆ Analytics
Eli Lilly beat earnings and raised its forecast as weight loss drug sales surged
Deterministic text analytics computed across all 2 sources. Frequency, entity overlap, and claim overlap — computed counts only. Nothing is rated true or false.
01
Frequency Analytics
The most common words and exact phrases across every report in this cluster. Computed counts only.
Top words
billionlillybeatestimatesforecastmounjarozepboundrevenueraisedweight
Top phrases
eli lillyweight loss drugbeat wall streetweight losswall street85 billionloss drugbeat wall
02
Entity Overlap
Names detected in the report text: which appear across multiple sources, and which only one source mentions.
Across multiple sources
- Eli Lilly · 2 sources
- Mounjaro · 2 sources
- Zepbound · 2 sources
Unique to one source
- Wall Street · Quartz
- CVS Health's · Quartz
03
Claim Overlap
Near-identical sentences found in two or more reports, versus sentences that appear in only one. Text match only — nothing is rated true or false.
Repeated across sources
No sentence appeared in more than one source.
Appears once
- "Mounjaro revenue jumped 91% to $9.9 billion and Zepbound brought in $4.9 billion as the drugmaker beat Wall Street estimates Mounjaro revenue jumped 91% to $9.9 billion and Zepbound brought in $4.9 billion as the drugmaker beat Wall Street estimates" · Quartz
- "CVS beat Wall Street expectations by a wide margin in the second quarter and raised its full-year profit forecast to as much as $8.10 per share CVS beat Wall Street expectations by a wide margin in the second quarter and raised its full-year profit forecast to as much as $8.10 per share" · Quartz
- "Eli Lilly now expects 2026 revenue to come in between $85 billion and $87 billion, up from a previous guidance of $82 billion and $85 billion." · CNBC